Duration of dilutional hyponatraemia (months) c 2.7 ± 6.5 3.2 ± 7.7 4.0 ± 9.3 Data are shown as mean ± standard deviation or number (%) for categorical variables. CHF, congestive heart failure ...

The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V 2-receptor antagonist, in patients with dilutional hyponatraemia. Methods and results A total of 118 ...